0001209191-18-004661.txt : 20180119 0001209191-18-004661.hdr.sgml : 20180119 20180119210030 ACCESSION NUMBER: 0001209191-18-004661 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180117 FILED AS OF DATE: 20180119 DATE AS OF CHANGE: 20180119 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Azelby Robert CENTRAL INDEX KEY: 0001656998 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36781 FILM NUMBER: 18538572 MAIL ADDRESS: STREET 1: 307 WESTLAKE AVE. NORTH, STE 300 CITY: SEATTLE STATE: WA ZIP: 98109 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Juno Therapeutics, Inc. CENTRAL INDEX KEY: 0001594864 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 463656275 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 DEXTER AVENUE NORTH, SUITE 1200 CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 2065821600 MAIL ADDRESS: STREET 1: 400 DEXTER AVENUE NORTH, SUITE 1200 CITY: SEATTLE STATE: WA ZIP: 98109 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-01-17 0 0001594864 Juno Therapeutics, Inc. JUNO 0001656998 Azelby Robert C/O 400 DEXTER AVENUE NORTH SUITE 1200 SEATTLE WA 98109 0 1 0 0 EVP & Chief Commercial Officer Common Stock 2018-01-17 4 M 0 2498 25.29 A 73330 D Common Stock 2018-01-17 4 M 0 26633 20.76 A 99963 D Common Stock 2018-01-17 4 S 0 21141 68.10 D 78822 D Common Stock 2018-01-17 4 S 0 7990 69.95 D 70832 D Stock Option (Right to Buy) 25.29 2018-01-17 4 M 0 2498 0.00 D 2026-11-07 Common Stock 2498 30836 D Stock Option (Right to Buy) 20.76 2018-01-17 4 M 0 26633 0.00 D 2027-02-06 Common Stock 26633 101208 D The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017. 1/48th of the shares subject to the option vested and became exercisable on December 8, 2016 and 1/48th of the shares subject to the option vests and becomes exercisable monthly thereafter. 1/48th of the shares subject to the option vested and became exercisable on March 7, 2017 and 1/48th of the shares subject to the option vests and becomes exercisable monthly thereafter. /s/ Zachary D. Hale, attorney-in-fact 2018-01-19